Literature DB >> 32860727

Measurement of Minimal Disease Activity in Psoriatic Arthritis Using the Patient-Reported Outcomes Measurement Information System-Physical Function or the Health Assessment Questionnaire Disability Index.

Erin Chew1, Jamie Perin2, Thomas Grader-Beck3, Ana-Maria Orbai3.   

Abstract

OBJECTIVE: To assess the interchangeability of the Health Assessment Questionnaire disability index (HAQ DI) with the Patient-Reported Outcomes Measurement Information System-Physical Function (PROMIS-PF) in the calculation of minimal disease activity (MDA) in psoriatic arthritis (PsA).
METHODS: Comprehensive PsA disease activity was collected concomitantly with the HAQ DI and the PROMIS-PF measures in a PsA cohort. The PROMIS-PF-based MDA definitions were built using the existing cross-walk between the scores: HAQ DI ≤0.5 equivalent to a PROMIS-PF T score of ≥41.3. We assessed agreement between MDA (MDA HAQ DI) and the PROMIS-PF MDA definitions (MDA PROMIS-PF short form 4a and MDA PROMIS-PF bank) at each visit and longitudinally (MDA state changes between consecutive visits) through the kappa statistic. The predictive value of the MDA PROMIS-PF for the MDA HAQ DI was assessed using receiver operator characteristic (ROC) curve analysis.
RESULTS: A total of 100 participants contributed 352 observations with up to 5 visits. The mean ± SD age was 52 ± 12 years, 60% were female, and 43% were in MDA at baseline. The kappa statistic for the PROMIS-PF-based MDA reflected excellent agreement with the HAQ DI MDA: κ = 0.94 (95% confidence interval [95% CI] 0.90-0.97) for MDA PROMIS-PF bank, and κ = 0.90 (95% CI 0.80-0.95) for MDA PROMIS-PF4a. Higher longitudinal agreement was seen between the MDA HAQ DI and the MDA PROMIS-PF bank versus the MDA PROMIS-PF4a between consecutive visits: κ values ranged between 0.81 and 0.94 versus a range between 0.72 and 0.84, respectively. The area under the ROC curve for predicting the MDA HAQ DI was 0.97 for the MDA PROMIS-PF bank and 0.95 for the MDA PROMIS-PF4a.
CONCLUSION: Excellent agreement was seen between the HAQ DI and the PROMIS-based MDA definitions both cross-sectionally and longitudinally. The PROMIS-PF bank and PROMIS-PF4a are accurate replacements for the HAQ DI in calculating MDA state in PsA.
© 2021, American College of Rheumatology.

Entities:  

Mesh:

Year:  2021        PMID: 32860727      PMCID: PMC7914287          DOI: 10.1002/acr.24433

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  25 in total

1.  Classification criteria for psoriatic arthritis: development of new criteria from a large international study.

Authors:  William Taylor; Dafna Gladman; Philip Helliwell; Antonio Marchesoni; Philip Mease; Herman Mielants
Journal:  Arthritis Rheum       Date:  2006-08

Review 2.  Psoriatic Arthritis.

Authors:  Christopher T Ritchlin; Robert A Colbert; Dafna D Gladman
Journal:  N Engl J Med       Date:  2017-03-09       Impact factor: 91.245

3.  Establishing a Common Metric for Physical Function: Linking the HAQ-DI and SF-36 PF Subscale to PROMIS(®) Physical Function.

Authors:  Benjamin D Schalet; Dennis A Revicki; Karon F Cook; Eswar Krishnan; Jim F Fries; David Cella
Journal:  J Gen Intern Med       Date:  2015-10       Impact factor: 5.128

4.  Physical function metric over measure: An illustration with the Patient-Reported Outcomes Measurement Information System (PROMIS) and the Functional Assessment of Cancer Therapy (FACT).

Authors:  Aaron J Kaat; Benjamin D Schalet; Joshua Rutsohn; Roxanne E Jensen; David Cella
Journal:  Cancer       Date:  2017-09-08       Impact factor: 6.860

5.  How rheumatologists assess disability in the current era needs an overhaul: focus on the Health Assessment Questionnaire.

Authors:  Marwan Bukhari; Alison Kent
Journal:  Rheumatology (Oxford)       Date:  2020-02-01       Impact factor: 7.580

6.  Improved responsiveness and reduced sample size requirements of PROMIS physical function scales with item response theory.

Authors:  James F Fries; Eswar Krishnan; Matthias Rose; Bharathi Lingala; Bonnie Bruce
Journal:  Arthritis Res Ther       Date:  2011-09-14       Impact factor: 5.156

Review 7.  Functional impairment measurement in psoriatic arthritis: Importance and challenges.

Authors:  Philip Mease; Vibeke Strand; Dafna Gladman
Journal:  Semin Arthritis Rheum       Date:  2018-05-23       Impact factor: 5.532

8.  Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score.

Authors:  Monika M Schoels; Daniel Aletaha; Farideh Alasti; Josef S Smolen
Journal:  Ann Rheum Dis       Date:  2015-08-12       Impact factor: 19.103

9.  Better assessment of physical function: item improvement is neglected but essential.

Authors:  Bonnie Bruce; James F Fries; Debbie Ambrosini; Bharathi Lingala; Barbara Gandek; Matthias Rose; John E Ware
Journal:  Arthritis Res Ther       Date:  2009-12-16       Impact factor: 5.156

10.  International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials.

Authors:  Ana-Maria Orbai; Maarten de Wit; Philip Mease; Judy A Shea; Laure Gossec; Ying Ying Leung; William Tillett; Musaab Elmamoun; Kristina Callis Duffin; Willemina Campbell; Robin Christensen; Laura Coates; Emma Dures; Lihi Eder; Oliver FitzGerald; Dafna Gladman; Niti Goel; Suzanne Dolwick Grieb; Sarah Hewlett; Pil Hoejgaard; Umut Kalyoncu; Chris Lindsay; Neil McHugh; Bev Shea; Ingrid Steinkoenig; Vibeke Strand; Alexis Ogdie
Journal:  Ann Rheum Dis       Date:  2016-09-09       Impact factor: 19.103

View more
  1 in total

1.  Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study.

Authors:  Ana-Maria Orbai; Laura C Coates; Atul Deodhar; Philip S Helliwell; Christopher T Ritchlin; Evan Leibowitz; Alexa P Kollmeier; Elizabeth C Hsia; Xie L Xu; Shihong Sheng; Yusang Jiang; Yan Liu; Chenglong Han
Journal:  Patient       Date:  2022-06-30       Impact factor: 3.481

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.